The objective of this pilot study is to evaluate the prevalence of biological aspirin resistance in women at risk for CHD taking low dose (81 mg) aspirin. Aspirin responsiveness will be measured with the VerifyNow device (Accumetrics; San Diego, CA). Those women identified as biologically resistant will be switched to aspirin 325 mg for 14 days and then re-tested for aspirin responsiveness.
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
PREVENTION
Masking
NONE
Enrollment
36
Aspirin 81mg and Aspirin 325mg, non-enteric coated, take one tablet by mouth daily
The Cardiac Center at Creighton University
Omaha, Nebraska, United States
Number of Women Aspirin Resistant
Aspirin responsive unit (ARU) \> 550 was considered to be aspirin resistant and correlates to less than 50% inhibition of platelet aggregation.
Time frame: Baseline
Number of Aspirin Resistant Who Became Responders After Increase to Aspirin 325 mg
Aspirin resistance was defined as ARU \> 550
Time frame: 2 weeks
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.